

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 68518-A/JPW/GJG/NDP	Serial No. 10/758,572
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants: Sharon Cohen-Vered et al.	
		Filing Date January 14, 2004	Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>AD</i>	5 1 2 6 2 4 9	6/30/92	Becker, et al.;			
<i>AD</i>	5 1 3 4 1 2 7	7/28/92	Stella, et al.;			
<i>AD</i>	5 3 7 6 6 4 5	12/27/94	Stella, et al.;			
<i>AD</i>	6 6 1 3 5 3 6	9/2/03	Mozes, et al.;			
<i>AD</i>	10 7 5 8 3 9 7	1/14/04	Sharon Cohen-Vered, et al.			

FOREIGN PATENT DOCUMENTS


	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<i>AD</i>	EPO 0 4 9 5 0 4 9	7/22/92	EPO;				
<i>AD</i>	WO 9 6 3 0 0 5 7	10/3/96	PCT;				
<i>AD</i>	WO 0 3 6 7 8 4 8	9/6/02	PCT;				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>AD</i>	Audibert et al. (1981) Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. <u>Nature</u> , 289:593-4;
<i>AD</i>	Axelrod, O. and Mozes, E. (1986) Analysis of the biological functions and fine specificity of (T,G)-A-L specific T cell clones. <u>Immunobiology</u> , 172:99-109;
<i>AD</i>	Bombardier C. et al. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. <u>Arthritis Rheum.</u> , 35:630-40;
<i>AD</i>	Conlon, P.J. (1983) A rapid biologic assay for the detection of interleukin 1. <u>J. Immunol.</u> , 134:1280-2;
<i>AD</i>	Dayan M. et al. (2000) Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. <u>J. Clin. Immunol.</u> , 20(3):187-94
<i>AD</i>	Dean G.S. et al. (2000) Cytokines and systemic lupus erythematosus. <u>Ann. Rheum. Dis.</u> , 59:243-51;
<i>AD</i>	Eilat, E., et al. (2000) Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3- based peptides of pathogenic autoantibody. <u>J. Clin. Immunol.</u> , 20:268-78;
<i>AD</i>	Eilat, E., et al. (2001) The mechanism by which a peptide based on complementarity determining region-1 of pathogenic anti-DNA antibody ameliorates experimental SLE. <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 98: 1148-53;
<i>AD</i>	Fricke, H. et al. (1991) Idiotype specific T-cell lines inducing experimental systemic lupus erythematosus in mice. <u>Immunology</u> , 73:421-7;
<i>AD</i>	Fricke, H. et al. (1990) Induction of experimental systemic lupus erythematosus in mice by immunization with a monoclonal anti-La autoantibody. <u>Int. Immunol.</u> , 2:225-30;
<i>AD</i>	Gearing, A.J.H. et al. (1994) Processing of tumor necrosis factor-alpha precursor by metalloproteinases. <u>Nature</u> , 370:555-7;
<i>AD</i>	Gijbels, K. et al. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. <u>J. Neuroimmunol.</u> , 41:29-34;
<i>AD</i>	Goetzl, E.J. et al. (1996) Matrix metalloproteinases in immunity. <u>J. Immunol.</u> , 156:1-4;
<i>AD</i>	Guedez, L. et al. (1996) The role of metalloproteinases and their inhibitors in hematological disorders. <u>Crit. Rev. Oncog.</u> , 7:205-25;

EXAMINER <i>AD</i>	DATE CONSIDERED <i>5/31/05</i> <i>corrected</i> <i>AD</i> <i>5/27/05</i>
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Applicants: Sharon Cohen-Vered et al.
Serial No.: 10/758,572
Filed: January 14, 2004
Exhibit A



Form PTO-1449

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.
68518-A/JPW/GJG/NDP

Serial No.
10/758,572

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants: Sharon Cohen-Vered et al.

Filing Date
January 14, 2004

Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
WO 9 9 3 1 0 6 6	6/24/99	PCT;				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Brosch N. et al. (2000) A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb is a Better Modulator of Experimental SLE than its Single Amino Acid-Substituted Analogs. <u>Cellular Immunology</u> , 205:52-61;
	Brosch N. et al. (2000) Characterization and Role in Experimental Systemic Lupus Erythematosus of T-cell Lines Specific to Peptides Based on Complementarity-Determining Region-1 and Complementarity-Determining Region-3 of a Pathogenic Anti-DNA Monoclonal Antibody. <u>Immunology</u> 99:257-264;
	Naparstek, Y. et al. (1989) Sequential Anti-Idiotypes Define Reciprocal Idiotopes on the Same Anti-DNA Antibody. <u>Clinical Immunology and Immunopathology</u> , 50:S106-S116; and
	Tsokos G.C. et al. (1999) Immune Cell Signaling Defects in Lupus: Activation, Anergy and Death. <u>Immunology Today</u> .

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed: January 14, 2004
Exhibit A

[illegible]

Applicants: Sharon Cohen-Vered et al.
Serial No.: 10/758,572
Filed: January 14, 2004
Exhibit A